PMID: 9432335Jun 1, 1997Paper

Omeprazole-based dual and triple therapy for the treatment of Helicobacter pylori infection in peptic ulcer disease: a randomized trial

Helicobacter
O PieramicoP Malfertheiner

Abstract

It was our goal to evaluate the efficacy and safety and patient compliance with omeprazole-based dual and triple therapy for eradication of Helicobacter pylori in peptic ulcer disease. One hundred seventy-five consecutive patients with H. pylori infection and associated active peptic ulcer were included. H. pylori infection was assessed by rapid urease test and histological analysis. Patients were randomized among three treatments: group 1 (56 patients): omeprazole, 20 mg bid, and amoxicillin, 1 gm bid, for 2 weeks; group 2 (61 patients): omeprazole, 20 mg bid, plus amoxicillin, 1 gm bid, and metronidazole, 500 mg bid, for 1 week; and group 3 (58 patients): omeprazole, 20 mg bid, plus amoxicillin, 1 gm bid, and clarithromycin, 500 mg bid, for 1 week. Ulcer healing and cure of infection were evaluated at 4 to 6 weeks after cessation of therapy. Eradication rate was calculated per-protocol and by an intention-to-treat analysis. At posttreatment endoscopy, duodenal ulcer was healed in 98.3% of patients. Eleven patients (6%) were lost to follow-up. H. pylori infection was treated successfully in 55% (95% confidence interval [CI] = 41%-69%) of patients of group 1; 86% (95% CI = 77%-95%) of group 2 (p < .001 vs. group 1); and 93% (95...Continue Reading

References

May 1, 1990·Digestive Diseases and Sciences·L C BaakC B Lamers
Oct 1, 1989·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M L GraysonR C Moellering
Feb 1, 1989·Gastroenterology·D Y Graham
Apr 15, 1985·The Medical Journal of Australia·B J MarshallR J Glancy
Oct 1, 1995·Gut·J LabenzG Börsch
Sep 1, 1995·The American Journal of Gastroenterology·K S GrahamD Y Graham
Jan 1, 1993·Journal of Hematotherapy·C D Hillyer, S J Wells
Nov 1, 1996·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A A van ZwetJ C Thijs

❮ Previous
Next ❯

Citations

Oct 26, 2000·Alimentary Pharmacology & Therapeutics·V StanghelliniR Corinaldesi
Jul 30, 2002·Alimentary Pharmacology & Therapeutics·P Della MonicaA Pera
Aug 30, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Siu-ka MakAndrew K M Wong
Jan 16, 2009·American Journal of Otolaryngology·Michael W CriddleJames Coticchia
Nov 4, 2000·Journal of Gastroenterology and Hepatology·W H WangS K Lam
Jul 6, 2014·Acta Biotheoretica·Dunja Šešelja, Christian Straßer
Nov 18, 2006·The Oncologist·Seth M CohenMichael L Grossbard
Apr 20, 2016·The Cochrane Database of Systematic Reviews·Alexander C FordPaul Moayyedi
Sep 23, 2020·Expert Review of Gastroenterology & Hepatology·Jianwei YunDekui Zhang
Sep 28, 1999·Scandinavian Journal of Gastroenterology·V EllenriederB Glasbrenner
Aug 6, 1998·Alimentary Pharmacology & Therapeutics·W A de BoerP M Schneeberger
Jun 10, 2000·Alimentary Pharmacology & Therapeutics·A ZulloA F Attili
Sep 21, 2001·Alimentary Pharmacology & Therapeutics·M Guslandi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.